Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H12O3 |
| Molecular Weight | 168.1898 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(OC)=CC(OC)=C1
InChI
InChIKey=LKUDPHPHKOZXCD-UHFFFAOYSA-N
InChI=1S/C9H12O3/c1-10-7-4-8(11-2)6-9(5-7)12-3/h4-6H,1-3H3
| Molecular Formula | C9H12O3 |
| Molecular Weight | 168.1898 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/spasfon_ct_9243.pdfCurator's Comment: Description was created using several sources including:
http://www.ema.europa.eu/docs/en_GB/document_library/contacts/ochassany_DI.pdf; https://www.ncbi.nlm.nih.gov/pubmed/14017697; https://www.ncbi.nlm.nih.gov/pubmed/15122041; https://www.ncbi.nlm.nih.gov/pubmed/17439513
Sources: http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/spasfon_ct_9243.pdf
Curator's Comment: Description was created using several sources including:
http://www.ema.europa.eu/docs/en_GB/document_library/contacts/ochassany_DI.pdf; https://www.ncbi.nlm.nih.gov/pubmed/14017697; https://www.ncbi.nlm.nih.gov/pubmed/15122041; https://www.ncbi.nlm.nih.gov/pubmed/17439513
1,3,5-trimethoxybenzene (trade name Spasfon (R), registered and marketed in France) is an antispasmodic drug acting on smooth muscle. It is indicated for symptomatic treatment of pain related to functional disorders of the gastrointestinal tract and biliary tract, urinary tract (renal colic) or gynecological pain, and to reduce early contractions during a pregnancy. It is widely prescribed in cases of intestinal disorders including infectious and other bowel disease, gastrointestinal symptoms, urinary tract and genital tract disease. Spasfon is produced as film-coated tablets and solution for injection. 1,3,5-Trimethoxybenzene is a key component of the Chinese rose odor. This compound is synthesized in three successive methylation steps from phloroglucinol, the initial precursor.
Originator
Sources: http://www.shp-asso.org/index.php?PAGE=lafon
Curator's Comment: In 2002, the Laboratory Louis Lafon was taken by Cephalon (USA) that acquired the entire portfolio of Lafon products sold in France including SPASFON(R) (phloroglucinol).
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Secondary | SPASFON(R) Approved UseIndicated for symptomatic treatment of pain related to functional disorders of the gastrointestinal tract
and biliary tract; treatment of spasm and acute pain of the urinary tract: renal colic; symptomatic treatment of painful spasm in gynaecology; adjuvant therapy for contractions during pregnancy, in combination with rest Launch Date1973 |
|||
| Palliative | SPASFON(R) Approved UseIndicated for symptomatic treatment of pain related to functional disorders of the gastrointestinal tract
and biliary tract; treatment of spasm and acute pain of the urinary tract: renal colic; symptomatic treatment of painful spasm in gynaecology; adjuvant therapy for contractions during pregnancy, in combination with rest Launch Date1973 |
|||
| Palliative | SPASFON(R) Approved UseIndicated for symptomatic treatment of pain related to functional disorders of the gastrointestinal tract
and biliary tract; treatment of spasm and acute pain of the urinary tract: renal colic; symptomatic treatment of painful spasm in gynaecology; adjuvant therapy for contractions during pregnancy, in combination with rest Launch Date1973 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
80 mg single, oral Recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Other AEs: Anaphylaxis... |
160 mg 3 times / day multiple, oral Studied dose Dose: 160 mg, 3 times / day Route: oral Route: multiple Dose: 160 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Abdominal pain, flatulenc... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Anaphylaxis | 80 mg single, oral Recommended |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
|
| Abdominal pain | 160 mg 3 times / day multiple, oral Studied dose Dose: 160 mg, 3 times / day Route: oral Route: multiple Dose: 160 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
| Constipation | 160 mg 3 times / day multiple, oral Studied dose Dose: 160 mg, 3 times / day Route: oral Route: multiple Dose: 160 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
| flatulenc | 160 mg 3 times / day multiple, oral Studied dose Dose: 160 mg, 3 times / day Route: oral Route: multiple Dose: 160 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| (1E,4E)-1,5-Bis(2,4,6-trimeth-oxy-phen-yl)penta-1,4-dien-3-one. | 2010-12-04 |
|
| Synthesis and antitumor activity of diterpenylhydroquinone derivatives of natural ent-labdanes. | 2010-09-17 |
|
| (E)-1-(2-Fur-yl)-3-(2,4,6-trimeth-oxy-phen-yl)prop-2-en-1-one. | 2010-09-15 |
|
| A carbene-carbene complex equilibrium. | 2010-08-11 |
|
| Synthesis and biological evaluation of a novel series of 2,2-bisaminomethylated aurone analogues as anti-inflammatory and antimicrobial agents. | 2010-07 |
|
| Mesit-yl(2,4,6-trimeth-oxy-phen-yl)borinic acid. | 2010-06-18 |
|
| Solvation of dichlorocarbene: complexation with aryl ethers. | 2010-01-14 |
|
| 6-(4-Bromo-phen-yl)-2-eth-oxy-4-(2,4,6-trimethoxy-phen-yl)nicotinonitrile. | 2009-10-31 |
|
| Ozonolysis of lignin models in aqueous solution: anisole, 1,2-dimethoxybenzene, 1,4-dimethoxybenzene, and 1,3,5-trimethoxybenzene. | 2009-08-15 |
|
| (E)-1-(4-Bromo-phen-yl)-3-(2,4,6-trimethoxy-phen-yl)prop-2-en-1-one. | 2009-03-28 |
|
| Development of a coupled diffusion denuder system combined with gas chromatography/mass spectrometry for the separation and quantification of molecular iodine and the activated iodine compounds iodine monochloride and hypoiodous acid in the marine atmosphere. | 2009-03-01 |
|
| Total synthesis of wasabidienones B1 and B0 via SIBX-mediated hydroxylative phenol dearomatization. | 2008-11-20 |
|
| A denuder-impinger system with in situ derivatization followed by gas chromatography-mass spectrometry for the determination of gaseous iodine-containing halogen species. | 2008-11-14 |
|
| C3 vanadium(V) amine triphenolate complexes: vanadium haloperoxidase structural and functional models. | 2008-10-06 |
|
| A xerogel-sequestered selenoxide catalyst for brominations with hydrogen peroxide and sodium bromide in an aqueous environment. | 2008-09-05 |
|
| Validation of a quantitative NMR method for suspected counterfeit products exemplified on determination of benzethonium chloride in grapefruit seed extracts. | 2008-08-05 |
|
| Leaf essential oil composition of three species of Myrcianthes from Monteverde, Costa Rica. | 2008-07 |
|
| Investigation of the dynamic stereochemistry of dimesityl-2,4,6-trimethoxyphenylmethane by complete lineshape analysis and 2D EXSY NMR spectroscopy. | 2008-04 |
|
| Sila-haloperidol, a silicon analogue of the dopamine (D2) receptor antagonist haloperidol: synthesis, pharmacological properties, and metabolic fate. | 2008-01 |
|
| Electron capture in charge-tagged peptides. Evidence for the role of excited electronic states. | 2007-12 |
|
| Transcriptomic and metabolite analyses of Cabernet Sauvignon grape berry development. | 2007-11-22 |
|
| Tissue-specific mRNA expression profiling in grape berry tissues. | 2007-06-21 |
|
| Bimolecular hole transfer from the trimethoxybenzene radical cation in the excited state. | 2007-06-07 |
|
| One-electron oxidation of alcohols by the 1,3,5-trimethoxybenzene radical cation in the excited state during two-color two-laser flash photolysis. | 2007-03-15 |
|
| Solvent-free iodination of organic molecules using the I(2)/urea-H(2)O(2) reagent system. | 2007-02-21 |
|
| The behavior of exciplex decay processes and interplay of radiationless transition and preliminary reorganization mechanisms of electron transfer in loose and tight pairs of reactants. | 2007-01-18 |
|
| Facile synthesis of 1,3,7-trihydroxyxanthone and its regioselective coupling reactions with prenal: simple and efficient access to osajaxanthone and nigrolineaxanthone F. | 2006-06-23 |
|
| Control of extremely fast competitive consecutive reactions using micromixing. Selective Friedel-Crafts aminoalkylation. | 2005-08-24 |
|
| Synthesis, characterization, and PGSE (1H and 19F) NMR diffusion studies on cationic (eta6- arene)Mn(CO)3+ complexes: boron counterion, ion pairing, and solvent dependences. | 2005-08-08 |
|
| Adsorption of single-ring organic compounds to wood charcoals prepared under different thermochemical conditions. | 2005-06-01 |
|
| The key role of phloroglucinol O-methyltransferase in the biosynthesis of Rosa chinensis volatile 1,3,5-trimethoxybenzene. | 2004-05 |
|
| Computational insight into the reaction intermediates in the glycosylation reaction assisted by donor heteroatoms. | 2003-02-07 |
|
| Two O-methyltransferases isolated from flower petals of Rosa chinensis var. spontanea involved in scent biosynthesis. | 2003 |
|
| Biosynthesis of the major scent components 3,5-dimethoxytoluene and 1,3,5-trimethoxybenzene by novel rose O-methyltransferases. | 2002-07-17 |
|
| Reactions of N-methyl-N-(4-biphenylyl)nitrenium ion with electron-rich arenes: laser flash photolysis and product studies. | 2002-04-10 |
|
| Metallocyclic receptors with Re(I)/Os(II)-based moieties: molecular photophysics and selective molecular sensing. | 2001-06-01 |
|
| Studies in polyphenol chemistry and bioactivity. 3.(1,2) stereocontrolled synthesis of epicatechin-4alpha,8-epicatechin, an unnatural isomer of the B-type procyanidins. | 2001-02-23 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2538427
Assays for halogenation by neutrophils and eosinophils from
the blood of normal volunteers and patients with eosinophilia were carried out using labeled with radioactive carbon 1,3,5-trimethoxybenzene at 1 X 10(-4) M (14C = 0.5 nCi/ml). Total amount of active halogen trapped by 1,3,5-trimethoxybenzene from eosinophils increases by over 2-fold as the added bromide concentration increases from 0 to 100 microM, with approximately 40 nmol of halogen trapped per million cells at the highest bromide level.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:03:24 GMT 2025
by
admin
on
Mon Mar 31 19:03:24 GMT 2025
|
| Record UNII |
00VJI3VG3D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000092189
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
210-673-4
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
69301
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
90060
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
SUB15620MIG
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
38716
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | RxNorm | ||
|
621-23-8
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
00VJI3VG3D
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
SUB49266
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
31038
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
C015560
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY | |||
|
DTXSID0045963
Created by
admin on Mon Mar 31 19:03:24 GMT 2025 , Edited by admin on Mon Mar 31 19:03:24 GMT 2025
|
PRIMARY |